NEOMED-LABS possesses a strong background and multiple years of experience in developing viral and bacterial manual and automated functional assays. Our team of experienced scientists has been working for many years with several validated assays used for GCLP clinical testing of vaccines from early to late-stage clinical development. Our experts work in close collaboration with clients to adapt, develop, and validate specific tests to evaluate the functional activity of their product. Ask our team how we can help you increase your throughput using our automation services to accelerate the progression of your product to commercialization.
Viral Neutralization Assay:
This method evaluates the impact of antibodies in human serum against the infectivity of viruses. Antibodies produced against a given virus will have the ability to interfere on the interaction with the host cell receptor, hence neutralizing the infectivity of the virus. The microplaque reduction neutralization test is used to evaluate the presence and to quantify the titre of those neutralizing antibodies. It is currently considered to be the gold standard for detecting and measuring antibodies that can neutralize viruses’ infectivity. NEOMED-LABS uses this automated test to evaluate the infectivity of multiple types of viruses. We help you set up the best assay conditions suited to your needs. Contact us for more details.
Hemagglutination Inhibition Assay:
The hemagglutination inhibition assay (HAI) is a method used for evaluating the concentration of antibodies in human serum. The HAI assay is used at NEOMED-LABS for the quantitative determination of the influenza virus and antibodies in human samples of subjects vaccinated with the seasonal flu vaccine. We work in close collaboration with our clients to set up the optimal HAI assay conditions adapted to their needs.
Human Serum Bactericidal Assay (hSBA):
The best and most relevant biological marker of protection remains the complement-mediated bactericidal activity. Our standardized serum bactericidal assay (SBA) evaluates functional antibodies that have been demonstrated as essential for protection. The SBA is one of the few tests that regroups the interaction between the pathogen, the antimicrobial substance, and the patient. NEOMED-LABS has validated and automated this test for the analysis of meningococcal vaccines. Contact us to determine how we can help you set up the best assay conditions suited to your needs.